PHARE: One-Year Trastuzumab Remains Standard for HER2-Positive Breast Cancer
A 6-month regimen of treatment with trastuzumab for HER2-positive breast cancer failed to show noninferiority with the standard 12-month treatment regimen after 3.5 years of follow-up in the open-label, randomized, phase III PHARE trial. (Source: Cancer Network)
Source: Cancer Network - July 3, 2013 Category: Cancer & Oncology Source Type: news

FDA Grants Genentech's Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
Application follows proposed new FDA pathway designed to help bring promising medicines to people with earlier stages of breast cancer faster (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 2, 2013 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: news

FDA grants Roche's Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early-stage breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 2, 2013 Category: Pharmaceuticals Source Type: news

FDA grants Roche's Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early-stage breast cancer. (Source: Roche Media News)
Source: Roche Media News - July 2, 2013 Category: Pharmaceuticals Source Type: news

Low-Dose Chemo for Low Toxicity in Breast CancerLow-Dose Chemo for Low Toxicity in Breast Cancer
Dr. Laura Orlando describes impressive early results in treating advanced HER2-positive breast cancer with a combination of trastuzumab and low-dose chemotherapy. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology Expert Interview Source Type: news

Anti-Cancer Agent Perjeta Approved for HER2-positive Inoperable or Recurrent Breast Cancer
Dear Investor, Please find attached a press release by Chugai. (Source: Roche Investor Update)
Source: Roche Investor Update - July 1, 2013 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche's Subcutaneous Herceptin for HER2 positive breast cancer
- New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients' time - Herceptin® is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (SIX: RO, ROG; OTCQX: RHHBY) is pleased to announce that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has today recommended EU approval of a subcutaneous formulation of Herceptin® (trastuzumab) for the treatment of patients with HER2-positive breast cancer. ...
Source: Roche Investor Update - June 28, 2013 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche's Subcutaneous Herceptin for HER2 positive breast cancer
- New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients' time - Herceptin® is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year (Source: Roche Media News)
Source: Roche Media News - June 28, 2013 Category: Pharmaceuticals Source Type: news

UK Lags Behind EU Counterparts In Uptake Of Oncology Biomarker Testing
Research reveals that the uptake of diagnostic testing amongst cancer patients in the UK trails behind that of other Western European markets. The data, which comes from Ipsos Healthcare's Global Oncology Monitor, shows that across three of the most highly-researched oncology biomarkers - HER2, KRAS and EGFR mutation - the proportion of relevant patients undergoing genetic testing in the UK was behind the EU4 average for the past few years. In fact, more often than not, the UK trailed each of the four individual markets... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 27, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

More Targets for Lung Cancer Therapy on the HorizonMore Targets for Lung Cancer Therapy on the Horizon
Dr. Maurie Markman reviews a recent article on HER2 mutations in lung cancer and considers whether HER2-targeting agents might be useful in these patients. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

BOLERO-3: Adding Everolimus Improves PFS in HER2+ Breast Cancer
The addition of everolimus (Novartis) to combination trastuzumab/vinorelbine leads to a significant improvement in progression-free survival compared with placebo in advanced and metastatic HER2-positive breast cancer. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
A high baseline level of soluble human epidermal growth factor receptor 2 (sHER2) was a prognostic indicator of shorter disease-free survival among patients with early-stage HER2-positive breast cancer, according to results from the North Central Cancer Treatment Group adjuvant trial N9831. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

HER2/neu and Diagnosis
HER2, which is also called HER2/neu, and HER-2, is the acronym for human epidermal growth factor receptor 2. Knowing your HER2 status is an important part of your diagnosis. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 19, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Automated vs Manual FISH for Evaluation of HER2 StatusAutomated vs Manual FISH for Evaluation of HER2 Status
Does the automation of HER2 FISH improve the accuracy of HER2 gene testing in breast biopsy specimens? BMC Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Targeting HER2 in Esophageal CancerTargeting HER2 in Esophageal Cancer
Human epidermal growth factor antagonists are being tested in HER2-positive gastric and gastroesophageal junction tumors. Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Tubular Carcinoma of the Breast
Tubular carcinoma is a rare type of invasive ductal carcinoma of the breast. Tubular carcinomas tend to be small, estrogen-receptor positive, HER2/neu negative. Your chance of recovery and survival after treatment for a tubular carcinoma is very good. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 14, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Hyperinsulinaemia promotes Her2 breast cancer metastasis
Epidemiological studies have associated both type 2 diabetes and hyperinsulinaemia with breast cancer in women. The Her2 oncogene is associated with metastasis and poor outcome. Ferguson and colleagues used a mouse model of Her2-mediated breast cancer to demonstrate that hyperinsulinaemia results in larger, more aggressive primary tumours, with more numerous lung metastases. Read the full article in Ferguson et al (2013) Endocrine-Related Cancer 20 391—401, DOI: 10.1530/ERC-12-0333. (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 12, 2013 Category: Endocrinology Source Type: news

HER2 screening recommended for lung adenocarcinoma patients
Researchers highlight the importance of testing for HER2 mutations in patients with non-small-cell lung cancer, adding to evidence that supports the use of HER2-targeted drugs in this population. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - June 6, 2013 Category: Cancer & Oncology Source Type: news

HER2 screening recommended for lung adenocarcinoma patients
Researchers highlight the importance of testing for HER2 mutations in patients with non-small-cell lung cancer, adding to evidence that supports the use of HER2-targeted drugs in this population. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - June 6, 2013 Category: Cancer & Oncology Source Type: news

Herceptin - A Targeted Biologic Therapy for...
Read a description of Herceptin (trastuzumab), how it works, about the side effects, and get some self-care tips. Herceptin is given for HER2 positive breast cancer as a targeted biologic therapy. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 5, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

ASCO: Afinitor Quells Herceptin Resistance
CHICAGO (MedPage Today) -- A study presented here may help unravel the issue of resistance to trastuzumab (Herceptin), a drug that is central to the treatment of HER2-positive breast cancer. (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - June 4, 2013 Category: OBGYN Source Type: news

A Wide Variety Of Advanced Cancers Harbor Abnormalities In HER2 Gene
The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression - among them mutations, amplifications, substitutions, and translocations - have been found in 14 different advanced solid tumors. The results of the study of more than 2,000 tumors, presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of these tumors might benefit from the three anti-HER2 therapies now in clinical use... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 4, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

HER2 screening recommended for lung adenocarcinoma patients
Researchers highlight the importance of testing for HER2 mutations in patients with non-small-cell lung cancer, adding to evidence that supports the use of HER2-targeted drugs in this population. (Source: MedWire News - Respiratory)
Source: MedWire News - Respiratory - June 4, 2013 Category: Respiratory Medicine Source Type: news

GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer
GlaxoSmithKline (GSK) plc today announced that its study of TYKERB/TYVERB® (lapatinib) in combination with chemotherapy in patients with HER2-positive advanced gastric cancer did not meet the primary endpoint of improved overall survival (OS) compared to chemotherapy alone. (Source: GSK news)
Source: GSK news - June 3, 2013 Category: Pharmaceuticals Source Type: news

HER2 Abnormalities Found In Many Advanced Cancers
We already know that an over-active HER2 growth factor gene features in breast and gastric cancers. Now a new study reports finding mutations and other abnormalities of the gene in 14 different advanced cancers. Massimo Cristofanilli, Director of the Jefferson Breast Center at the Kimmel Cancer Center and Thomas Jefferson University Hospital, announced the study results at an oral presentation during the annual meeting of the American Society of Clinical Oncology (ASCO), which is taking place in Chicago until Tuesday... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 3, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Novartis' Afinitor Phase III trial demonstrates efficacy in delaying tumour growth
Switzerland-based Novartis has announced encouraging results from a pivotal Phase III trial demonstrating the efficacy of Afinitor (everolimus) tablets in significantly delaying tumour growth in HER2-positive advanced breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - June 3, 2013 Category: Pharmaceuticals Source Type: news

Abnormalities in HER2 gene found in wide variety of advanced cancers
(Thomas Jefferson University) The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes' expression -- among them mutations, amplifications, substitutions, and translocations -- have been found in 14 different advanced solid tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 2, 2013 Category: Global & Universal Source Type: news

PIK3CA Mutations Negatively Affect Survival in Trastuzumab-Treated HER2-Positive Breast Cancer
A study confirmed that PIK3CA mutations negatively affect survival in patients with HER2-positive breast cancer treated with the anti-HER2 therapy trastuzumab. (Source: Cancer Network)
Source: Cancer Network - May 6, 2013 Category: Cancer & Oncology Source Type: news

HER2-Targeted Therapies Could Benefit Lung Cancer Patients With HER2 Mutations
A new study shows that drugs targeting HER2 might provide good results in the rare non-small-cell lung cancer (NSCLC) patients with HER2 mutations. (Source: Cancer Network)
Source: Cancer Network - May 1, 2013 Category: Cancer & Oncology Source Type: news

Patients With Lung Cancer Who Carry Specific HER2 Mutations May Benefit From Certain Anti-HER2 Treatments
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations. Although genetic changes cause tumor cells to make too much of the HER2 protein in up to 20% of lung cancers, mutations in the HER2 gene occur in only 1-2% of lung cancers... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 24, 2013 Category: Consumer Health News Tags: Lung Cancer Source Type: news

HER2-Targeted Drugs Useful in Some Lung Cancer PatientsHER2-Targeted Drugs Useful in Some Lung Cancer Patients
Drugs such as trastuzumab have already transformed the treatment of breast cancer. New research suggests they may also be useful in lung cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 24, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

HER2-Positive NSCLC Yields to Targeted Agents (CME/CE)
(MedPage Today) -- A majority of patients with HER2-positive lung cancer had objective responses or stable disease when they received anti-HER2 agents in addition to chemotherapy, a small clinical study showed. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 22, 2013 Category: Primary Care Source Type: news

Tumors with ALK rearrangements can harbor more mutations
(International Association for the Study of Lung Cancer) The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung adenocarcinoma cases harbor KRAS mutation, EGFR mutation, or ALK translocation, and an additional 5 percent or so have been shown to have mutations involving BRAF, PIK3CA, HER2, MET, MEK1, NRAS, and AKT. In the vast majority, these driver mutations are mutually exclusive. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2013 Category: Global & Universal Source Type: news

Bevacizumab No Extra Help in Metastatic Breast CancerBevacizumab No Extra Help in Metastatic Breast Cancer
In metastatic breast cancer, adding bevacizumab to first-line chemotherapy improves progression-free survival (PFS) when tumors are HER2-negative - but not, as researchers just found out, when they're HER2-positive. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 19, 2013 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Merrimack completes patient enrolment in one cohort of Phase 2 study into breast cancer agent
Biopharmaceutical company Merrimack Pharmaceuticals has completed patient enrolment in one group of a two-cohort randomised Phase 2 study of MM-121 in HER2-negative breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - April 16, 2013 Category: Pharmaceuticals Source Type: news

Breast cancer drug receives 'breakthrough therapy' designation from FDA
An experimental drug being investigated for the treatment of advanced breast cancer by researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center this week received "breakthrough therapy" designation from the U.S. Food and Drug Administration.   In a clinical trial, patients with advanced breast cancer that was estrogen-receptor positive (ER+) and HER2-negative (HER2-), and who were given palbociclib (PD 0332991, Pfizer Inc.) in addition to the standard anti-estrogen treatment of letrozole had significantly higher progression-free survival — the lengt...
Source: UCLA Newsroom: Health Sciences - April 13, 2013 Category: Universities & Medical Training Source Type: news

Overwhelming Evidence Adds A Major New Target In Breast Cancer: Androgens Including Testosterone
Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors. "This is a continuing line of work with all evidence pointing toward the addition of the androgen receptor as potential target and useful marker in all of the major subtypes of breast cancer," says Jennifer Richer, PhD, investigator at the University of Colorado Cancer Center and co-director of the CU Cancer Center Tissue Processing and Procurement Core... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 12, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

AACR: Results of THYME Trial Show the Time Is Not Right for AZD8931
The THYME trial testing AZD8931 in advanced HER2-low breast cancer failed to reach the primary endpoint of progression-free survival, according to results of the phase II trial presented at the 2013 AACR meeting in Washington, DC. (Source: Cancer Network)
Source: Cancer Network - April 11, 2013 Category: Cancer & Oncology Source Type: news

Roche Group posts strong sales growth in the first quarter
Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven by cancer medicines and Tamiflu; Successful launches of Kadcyla and Perjeta strengthen HER2-positive breast cancer franchise; Diagnostics sales rise 1% to 2.4 billion Swiss francs; strong growth in Professional Diagnostics (+5%), decline in Diabetes Care (-5%); Full-year outlook confirmed (Source: Roche Investor Update)
Source: Roche Investor Update - April 11, 2013 Category: Pharmaceuticals Source Type: news

Roche Group posts strong sales growth in the first quarter
Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven by cancer medicines and Tamiflu; Successful launches of Kadcyla and Perjeta strengthen HER2-positive breast cancer franchise (Source: Roche Media News)
Source: Roche Media News - April 11, 2013 Category: Pharmaceuticals Source Type: news

Mutation Status May Guide Treatment for HER2 Breast CancerMutation Status May Guide Treatment for HER2 Breast Cancer
It is likely that biomarkers will eventually help determine which therapy is best in HER2-positive disease. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Combined HER2 Targeted Therapy Without Chemotherapy Will Likely Benefit Certain Breast Cancer Patients
Is the era of targeted therapy for breast cancer at hand? It could be, said experts at the Lester and Sue Smith Breast Center at Baylor College of Medicine - at least for a certain population of women. In a report that appears online in the Journal of Clinical Oncology, the researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2 positive) may benefit from a combination of targeted treatments that zero in on the breast cancer cells themselves... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 10, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

AACR news: Studies show increasing evidence that androgen drives breast cancer
(University of Colorado Denver) Estrogen and progesterone receptors, and the gene HER2 -- these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: Androgen receptors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2013 Category: Cancer & Oncology Source Type: news

RNA-Based Determination of ESR1 and HER2 ExpressionRNA-Based Determination of ESR1 and HER2 Expression
Hormone and HER2 receptors are the most important breast cancer biomarkers, and additional objective and quantitative test methods such as mRNA-based quantitative analysis are urgently needed. Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 8, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

AACR: T-DM1 Most Effective in Breast Cancer Patients With High HER2 Expression
Researchers participating in the phase III EMILIA trial have identified tumor biomarkers that can identify patients that are more likely to benefit from T-DM1. In the trial, women whose tumors had higher HER2 expression were most likely to benefit from the therapy. (Source: Cancer Network)
Source: Cancer Network - April 8, 2013 Category: Cancer & Oncology Source Type: news

T-DM1 and the Dawn of Precision MedicineT-DM1 and the Dawn of Precision Medicine
Dr. Maurie Markman sees T-DM1, which combines antitumor activities of trastuzumab and HER2-targeted delivery of a cytotoxic agent, as an example of the precision medicine we can expect in the future. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 20, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

HER2-Positive Breast Cancer Patients Prefer Faster Subcutaneous Administration Of Herceptin® (Trastuzumab) To IV
Further research also reveals quicker administration of Herceptin could save NHS £15m compared to current practice1 Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland. The primary reasons for preferring SC administration given by patients in the trial were less pain/discomfort and time saving... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

New Treatment For Advanced HER2+ Breast Cancer Patients As Perjeta® (Pertuzumab) Gets Regulatory Green Light
Perjeta works synergistically with Herceptin® (trastuzumab) to extend survival and stall disease progression for longer than the gold standard of care[i] From now on, patients with advanced HER2-positive breast cancer could benefit from the new personalised breast cancer treatment, Perjeta - which is now authorised for use in the UK. Perjeta has been granted a licence by the European Medicines Agency (EMA), for patients with previously untreated advanced HER2-positive breast cancer in combination with the current gold standard-of-care, Herceptin and chemotherapy (docetaxel)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Breast cancer drug 'biggest boost since Herceptin'
Thousands of women with a type of advanced breast cancer could benefit from a drug described as the biggest step-change in treatment of the disease since Herceptin was introduced in 1999. (Source: Telegraph Health)
Source: Telegraph Health - March 14, 2013 Category: Consumer Health News Tags: perjeta herceptin tumour roche breast cancer HER2 Source Type: news

Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC). PERJETA is approved in combination with Herceptin (trastuzumab) and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - March 5, 2013 Category: Pharmaceuticals Source Type: news